CRISPR Therapeutics AG (NASDAQ:CRSP) is a biotechnology company focused on developing transformative gene-based medicines. The company is a leader in CRISPR/Cas9 gene-editing technology, which has the potential to treat a wide range of genetic diseases. CRSP competes with other biotech firms like Editas Medicine and Intellia Therapeutics in the gene-editing space.
On January 22, 2026, Samarth Kulkarni, CEO of CRSP, sold 60,000 shares at $60.23 each. This transaction left him with 134,201 shares. Despite this insider sale, CRSP's stock recently closed at $54.21, marking a 4.71% decline from the previous day. This drop contrasts with the broader market's gains, as highlighted by the S&P 500, Dow, and Nasdaq.
CRSP's recent stock performance has been mixed. Before the latest trading session, the stock had risen by 3.93%, outperforming the Medical sector's 0.92% gain and the S&P 500's 1.57% increase. However, over the past month, CRSP's stock fell by 2.91%, underperforming the Medical sector's 2.08% gain and the S&P 500's 1.15% rise.
Investors are eagerly awaiting CRSP's upcoming earnings report. The company is expected to report an EPS of -$1.15, a significant 161.36% decrease from the previous year. Revenue is anticipated to be $4 million, marking an 88.78% decline. For the full year, earnings are projected at -$6.33 per share, with revenue of $8.54 million.
CRSP's financial metrics reveal challenges. The company has a negative P/E ratio of -11.37, indicating unprofitability. The high price-to-sales ratio of 157.68 suggests investors pay a premium for each sales dollar. Despite these challenges, CRSP maintains a low debt-to-equity ratio of 0.11 and a strong current ratio of 16.22, reflecting a conservative capital structure and robust liquidity.
